Double-blind, placebo controlled phase II repeat dose study of the safety and efficacy of three parallel loading and maintenance dose regimens of CG100649 versus placebo for the treatment of primary osteoarthritis in male subjects.

Trial Profile

Double-blind, placebo controlled phase II repeat dose study of the safety and efficacy of three parallel loading and maintenance dose regimens of CG100649 versus placebo for the treatment of primary osteoarthritis in male subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Polmacoxib (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Therapeutic Use
  • Sponsors CrystalGenomics
  • Most Recent Events

    • 29 Mar 2012 Planned patient number is 363 according to European Clinical Trials Database.
    • 04 Oct 2010 Status changed from recruiting to completed, based on a CrystalGenomics media release.
    • 18 Dec 2008 Primary endpoint 'Western Ontario and McMaster Universities Osteoarthritis Index' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top